ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2594

Comparing Immunogenicity Between TVB-009 and Reference Denosumab in Healthy Adults and Participants with Postmenopausal Osteoporosis
Abstract Number: 2496

Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score
Abstract Number: 0535

Comparing Perspectives of Physician-Assessed and Self-Reported Inflammatory Back Pain: Insights from the SHERPAS Cohort
Abstract Number: 1495

Comparing the 0-10 Physician Global Assessment Scale to Categorical Disease Activity States among Pediatric Patients with SLE
Abstract Number: 1089

Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Abstract Number: 0841

Comparing the Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Outcomes in Lupus Nephritis: A Retrospective Cohort Study
Abstract Number: 1638

Comparison and Assessment of the All of Us Dataset for Epidemiologic Studies of Systemic Lupus Erythematosus (SLE) Among African American Women
Abstract Number: 2263

Comparison of a Patient-Reported Disease Activity Measure with Physician-Based Indices in Rheumatoid Arthritis Patients in Nigeria
Abstract Number: 0342

Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study
Abstract Number: 2514

Comparison of Demographics and Outcomes of Inpatient Hospitalization of Severe Asthma Patients with Eosinophilic Granulomatosis with Polyangitis. A Study on the National Inpatient Sample Database
Abstract Number: 2689

Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study
Abstract Number: 1720

Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
Abstract Number: 1970

Comparison of Optical Imaging with Musculoskeletal Ultrasound in Assessment of PIP Joints of Systemic Lupus Erythematosus Patients
Abstract Number: 0290

Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey
Abstract Number: 1593

Comparison of rituximab induction and maintenance regimens in ANCA-associated vasculitis: PK/PD modelling approach in real-world patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].